Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356408 · ClinicalTrials.gov registry record · Phase 3
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
NCT00356408 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 106 participants.
The verdict
NCT00356408, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).
Interventions
- BIOLOGICAL Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356408
The ClinicalTrials.gov registry entry for NCT00356408 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab pegol is the first listed.
NCT00356408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356408 about?
NCT00356408 is a clinical study titled "Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease". This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).
What is the current status of trial NCT00356408?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2007-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00356408?
The interventions under investigation include: Certolizumab pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT00356408?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.